United States
Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with over $350 million under management. We seek transformative, cutting-edge life sciences technologies at all development stages. Our portfolio comprises over 40 companies that develop breakthrough solutions to substantial unmet needs. Pontifax invests in breakthrough innovation regardless of therapeutic area or development stage. We establish our own companies as well as partner with existing managements to nurture start-ups to maturity. Pontifax takes a hands-on approach in its portfolio management and is deeply involved in charting the course of each company. Website: www.pontifax.com
65
Total Investments
51
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Biotechnology, Pharmaceutical
Funding Stage
Series A
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Pontifax
Recent Investments (65)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series A | •••••• | Oct 2025 | |
| Early VC | •••••• | Dec 2024 | |
| Seed | •••••• | Jun 2024 | |
| Series A | •••••• | May 2024 | |
| Post-IPO Equity | •••••• | Apr 2024 | |
•••• ••••
|
Series C | •••••• | Oct 2023 |
|
•••• ••••
|
Series B | •••••• | Aug 2023 |
|
•••• ••••
|
Series C | •••••• | Jan 2023 |
|
•••• ••••
|
Venture Round | •••••• | Dec 2022 |
|
•••• ••••
|
Series B | •••••• | Mar 2022 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
